Biocon Limited has informed the Exchange about Agreements

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.3%Reaction day

₹349.70

prior close

₹352.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.4%+0.9% vs market

Pharmaceuticals peers, median of 150sector+0.6%+0.7% vs sector

On the reaction day the stock moved 0.9 pts more than Nifty Midcap 150 and 0.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.5

15m

+0.1

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.3+0.4+0.9+0.6+0.7

Next day

+1.9+1.1+0.9+1.4+0.5

+3.7+0.9+2.8+1.4+2.3

+5.6+0.9+4.7+1.0+4.6

+7.1+1.0+6.1+1.0+6.1

+8.7+1.0+7.7+1.6+7.1

+5.5+0.6+4.9+0.6+4.9

15d

+14.1+0.5+13.6+3.8+10.2

+11.0-2.0+13.0+0.9+10.0

+0.7-4.1+4.7-3.7+4.4

-2.4-3.4+0.9-3.6+1.1

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon Limited's board approved buying 1,125 Optionally Convertible Debentures (OCDs) of its unlisted subsidiary Biocon Biologics Limited from Goldman Sachs for a total consideration of USD 198.50 million (about Rs. 1,675 crore at face value of Rs. 1 crore per OCD). The deal involves 1,047 OCDs from Goldman Sachs India AIF Scheme-2 and 78 OCDs from Goldman Sachs India AIF Scheme-1. These OCDs came with special rights for Goldman Sachs, including the ability to appoint directors, first right on share subscriptions, and veto power over capital structure changes at Biocon Biologics. By purchasing these instruments, Biocon is effectively buying out a key financial investor in its biologics arm. The transaction is not classified as a related-party deal.

Likely market impact

This is a strategic positive for Biocon shareholders — it consolidates the parent company's control over Biocon Biologics (its key biosimilars growth engine), simplifies the subsidiary's cap table, and removes a financially-motivated investor's special rights. The ~$198M cash outflow may pressure near-term liquidity but should be viewed as long-term value-accretive, giving Biocon full strategic flexibility over its biologics franchise.